Table of Contents
The first office of Axsome Therapeutics had three desks, no windows and so little natural light that the people who worked there started calling it the broom closet. It was in Rockefeller Center. The year was 2012, and Herriot Tabuteau had just walked away from two decades on Wall Street to start a drug company targeting central nervous system disorders, a field that most major pharmaceutical companies had been quietly exiting for years because the science was too hard and the returns too uncertain.
Nobody believed in him. That part he has said himself.
Thirteen years later, Axsome Therapeutics trades on the Nasdaq with a market capitalisation of $6.1 billion. The company has three FDA-approved drugs on the market and five more in late-stage development, targeting conditions that affect an estimated 150 million Americans. In 2025, Forbes placed Tabuteau on its global billionaires list with a net worth of $1.1 billion, making him the first person born in Haiti to appear in that ranking. He holds approximately 15% of Axsome's stock and is listed as the inventor on more than 200 patents.
From Port-au-Prince to the Upper East Side
Tabuteau was born in Haiti. He has described his early years there as marked by physical, nutritional and emotional hardship, and credits that experience with giving him the resilience that has defined the decades since. At nine years old, he left his mother and moved to New York City to live with his father and adoptive mother on Manhattan's Upper East Side.
The neighbourhood was not incidental. His parents worked at Rockefeller University, one of the world's premier biomedical research institutions. The family home was one city block from its campus, three blocks from Memorial Sloan Kettering Cancer Center and within walking distance of the Manhattan Eye, Ear and Throat Hospital and Cornell University's School of Medicine. Growing up inside that environment planted something early. He credits his father, who is from Haiti, with shaping his work ethic. He credits his mother, who was born in Harlem and was involved in the Civil Rights movement in the 1960s, with shaping his historical perspective and his love of art and literature.
He attended Xavier High School in Manhattan. From there he went to Wesleyan University in Connecticut, graduating in 1989 with a degree in molecular biology and biochemistry. His plan at that point was neurosurgery. He went to Yale University School of Medicine and completed his MD. He was, by every academic measure, on the path.
Then he watched his professors.
The pivot into finance
What he observed at Yale was not what he expected. The physicians around him, accomplished and credentialed, were visibly unhappy. He has cited that observation as the reason he changed direction. Where others would have pressed on toward surgery, Tabuteau went to Goldman Sachs, joining the healthcare investment banking group after completing his medical degree.
It was the beginning of nearly two decades in finance. He moved from Goldman Sachs to Banc of America Securities, where he was a senior healthcare research analyst covering the hospital supplies sector. He then went to Kingdon Capital as healthcare analyst. His final position before founding Axsome was as a founding member, senior analyst and partner at Healthco/S.A.C. Capital, a large healthcare hedge fund, where he ran the biotechnology, genomics and instrumentation portfolios.
Those years on Wall Street gave him something that most biotech founders lack: a precise, investor-grade understanding of where the pharmaceutical industry was creating value and where it was failing patients. The gap he kept seeing was in the brain. Conditions like major depressive disorder, Alzheimer's agitation and narcolepsy were widespread, devastating and chronically under-served. The large companies were retreating from the science because of its complexity. Tabuteau saw that as the opportunity.
Building Axsome
He founded Axsome in 2012 with his own money, backed by family and friends. There was no venture capital, no institutional funding in the early phase, just a conviction and the broom closet in Rockefeller Center. The company's name was deliberate. Axsome is drawn from two parts of a nerve cell: the axon and the soma.
His approach broke with industry convention in two critical ways. First, he built a pipeline of multiple drug candidates rather than concentrating everything on a single compound. Most small biotechs go all in on one drug because they cannot afford anything else. Axsome ran several simultaneously. Second, he conducted clinical trials in-house rather than outsourcing them, which the industry treats as standard practice. Running trials internally allowed Axsome to complete Phase III studies at 30% to 50% below standard industry cost, preserving capital during years when the company had no revenue and the stock sat below $10 for extended periods.
The early years were long and difficult. Wall Street was skeptical. The stock did not move for years. Nick Pizzie, Axsome's chief financial officer, put it plainly: "Nobody believed in Axsome years ago, and I think there's still a lot of unbelievers. It's a show-me story."
The drugs that changed everything
The first major turn came in October 2022 when the FDA approved Auvelity, a treatment for major depressive disorder. Auvelity is a combination of dextromethorphan and bupropion and represents the first new class of oral antidepressant approved in decades. Unlike traditional serotonin-based antidepressants that can take six to eight weeks to show effect, Auvelity was shown in trials to produce improvements within a week. The FDA approval sent Axsome's stock up 65% in a single week.
Auvelity generated $507 million in US revenue in 2025, a 74% increase over the prior year. Tabuteau believes its peak annual revenue potential sits between $1 billion and $3 billion, with patent protection running to at least 2038. The drug's commercial trajectory has been central to repositioning Axsome from an unproven small-cap biotech into a credible commercial biopharmaceutical company.
The second commercial product, Sunosi, a treatment for excessive daytime sleepiness, was acquired in 2022 for $53 million. Tabuteau then sold the non-US rights for $66 million while retaining full US control, generating a profit on the acquisition before the product had fully ramped. Sunosi now generates more than $100 million annually in US revenue.
The third is Symbravo, approved by the FDA in January 2025 for the acute treatment of migraine and launched commercially in June 2025.
The next inflection point is a supplemental NDA for AXS-05 in Alzheimer's disease agitation, which the FDA accepted with Priority Review. A decision is expected April 30, 2026. If approved, analysts project the drug could generate between $1.5 billion and $3 billion annually, given the absence of safe, effective non-antipsychotic options in that market.
Tabuteau has said Axsome's full portfolio, if everything in the pipeline succeeds, could eventually generate $16.5 billion in annual revenue, placing it among the top 25 pharmaceutical companies in the world. He has not gone on media record about his own wealth or his place on the Forbes list. He has given no media interviews since 1998, with one exception, a Forbes profile published in 2025 that marked his first public conversation with a journalist about his company in nearly three decades.
On weekends, he can be found in New York City parks doing outdoor science experiments with his two children, boy-girl twins. The broom closet is a long way behind him.
